TRENDS

Large Gap in Performance of New Drugs; Products Including Clenafin, Uptravi Doing Well

November 22, 2017
By Reiji Anasako Drug makers’ April-September business results were driven by a weaker yen and growth in sales of global products. The domestic market, however, was sluggish due to the growing use of generics, particularly authorized generics, along with declining…

To read the full story

TRENDS

By Reiji Anasako

Kyowa Hakko Kirin’s first and only Rituxan (rituximab) biosimilar in Japan is showing a faster-than-expected uptake in the market, with the company racking up 4.3 billion yen from the cancer drug in 2018, far beyond its initial 3.2 billion yen…

Members of a key reimbursement policy panel appear to be becoming more and more open to the industry’s call for…

By Takashi Ebisawa

A series of drug makers restructured or sold off production facilities in FY2018. Others dissolved or withdrew from the pharmaceutical business altogether. The entry of generics and transfer of products triggered these moves, but the underlying factor was the impact…

By Philip Carrigan

With a cursory glance, recruitment is easily defined. We’re here to help place candidates into the vacancies our clients need to fill. Armed with a pen and paper, you could even map out the process.• We study the market• We…